Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Braftovi | encorafenib | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Braftovi and Mektovi | encorafenib and binimetinib | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
| Tecartus | brexucabtagene autoleucel | Mantle cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kineret | anakinra | Still's disease | Withdrawn | |||
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
| Saxenda | liraglutide | Chronic weight management in adults | Do not reimburse | Complete | ||
| Rinvoq | upadacitinib | Psoriatic Arthritis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | venetoclax | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 11, 2024